APLS — Apellis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.25bn
- $5.30bn
- $1.00bn
U.S. STOCKS ON THE MOVE-Adobe, Foot Locker, Occidental Petroleum
U.S. STOCKS ON THE MOVE-Southwest Gas, Amtech Systems, Freight Technologies
Apellis falls after concerns over eye disease drug approval in EU
Apellis says EU regulator panel may not back its eye disease drug (updated)
Apellis says EU regulator panel may not back its eye disease drug
Brief: Apellis Pharmaceuticals Says Empaveli Provided Long-Term Control Of PNH In New Data Presented At Ash Annual Meeting
U.S. RESEARCH ROUNDUP- Carvana, Constellation Brands, CSG Systems International
Brief: Apellis Pharmaceuticals Updated U.S. Prescribing Information For Syfovre
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
Apellis down as Citron cautions of likely FDA warning letter
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co., Costco Wholesale, Idexx Laboratories
Apellis Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Apellis Pharmaceuticals Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE (pegcetacoplan injection) for Geographic Atrophy
U.S. STOCKS ON THE MOVE-Frontdoor, gold miners, UniFirst
U.S. STOCKS ON THE MOVE-ARS Pharma, AMC, Eli Lilly
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Akili, Tesla
U.S. STOCKS ON THE MOVE-Tesla, Mirati Therapeutics, Exxon Mobil
Apellis Pharma gains as J.P.Morgan upgrades rating on eye drug sales